- Home
- MLTX vs KBDC Comparison
MLTX vs KBDC Comparison
Compare MLTX & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MLTX | KBDC |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.8M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MLTX | KBDC |
|---|---|---|
| Price | $16.71 | $14.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $22.22 | $15.80 |
| AVG Volume (30 Days) | ★ 3.5M | 405.8K |
| Earning Date | 02-25-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 12.87% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $193.84 |
| Revenue Next Year | N/A | $9.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $13.06 |
| 52 Week High | $62.75 | $17.99 |
Technical Indicators
Market Signals| Indicator | MLTX | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 59.35 | 50.15 |
| Support Level | $15.70 | $14.39 |
| Resistance Level | $18.80 | $15.20 |
| Average True Range (ATR) | 1.20 | 0.34 |
| MACD | 0.44 | 0.04 |
| Stochastic Oscillator | 73.51 | 63.72 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.